BioMimetic Therapeutics Reports 2008 Fourth Quarter and Year End Results.
Business Wire › March 12, 2009
Linked as:
Extract
BioMimetic Therapeutics Reports 2008 Fourth Quarter and Year End Results.
Corporate Highlights:
* Enrollment in U.S. foot and ankle pivotal trial completed with 436 patients enrolled * Enrollment in EU foot and ankle clinical trial completed with 108 patients enrolled * Favorable clinical results in the Canadian foot and ankle pilot clinical trial for Augment Injectable Bone Graft * Favorable clinical results in the Augment Injectable Swedish distal radius fracture pilot study * United States Patent Office issued patent number 7,473,678 that will protect the Company's Augment product line, as well as certain other PDGF product formulations, until at least June 2025 FRANKLIN, Tenn. -- BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its financial results as of and for the three and twelve months ended December 31, 2008. For the...See the full content of this document
Sponsored links
